Enhancing in vitro cytotoxicity of doxorubicin against MCF-7 breast cancer cells in the presence of water-soluble β-cyclodextrin polymer as a nanocarrier agent

• Published in: Polymer bulletin (Berlin, Germany) Germany), 2022-03, Vol.79 (3), p.1555-1569
• Main Authors: Gholam-Hosseinpour, Maryam, Karami, Zahra, Hamedi, Sepideh, Mehri Lighvan, Zohreh, Heydari, Abolfazl
• Format: Article
• Language: English
• Subjects: Addition polymerization; Anticancer properties; Breast cancer; Characterization and Evaluation of Materials; Chemistry; Chemistry and Materials Science; Complex Fluids and Microfluidics; Crosslinking; Cyclodextrins; Cytotoxicity; Doxorubicin; Epichlorohydrin; Inclusion complexes; Nanoparticles; NMR; Nuclear magnetic resonance; Organic Chemistry; Original Paper; Penicillin; Physical Chemistry; Polymer Sciences; Polymers; Soft and Granular Matter; Spectrum analysis; Sustained release; Thermogravimetric analysis; Water chemistry; Zeta potential
• ISSN: 0170-0839; 1436-2449
• DOI: 10.1007/s00289-021-03569-1

This study was aimed to evaluate the impact of water-soluble β -cyclodextrin polymer ( β -CDP), as a nanocarrier, on the therapeutic efficacy of the commercial doxorubicin (DOX). The β -CDP was synthesized by cross-linking of β -CD using epichlorohydrin. The chemical structure of the cross-linked β -CDP was verified by NMR and thermogravimetric analysis. The solubility of β -CDP in water was around 880 g in 1000 mL. Next, the DOX/ β -CDP was formulated by the addition of the polymer into the various concentrations of DOX in a weight ratio of 1:10 and 1:20 (DOX: β -CDP). The formation of the inclusion complex of DOX with β -CDP was studied by UV–Vis spectroscopy. The UV–Vis spectra of DOX/ β -CDP formulations show the appearance of the absorption peak at 480 nm and a significant decrease in the absorbance intensity of DOX signal compared to DOX solution. This verified the formation of the DOX/ β -CDP complex and also the presence of free DOX in the DOX/ β -CDP formulation. The hydrodynamic size of DOX/ β -CDP formulation was obtained in the range of nanometer, and the complexion of DOX by β -CDP leads to a negative shift in the zeta potential. In vitro release profile shows a burst release followed by sustained release of DOX from DOX/ β -CDP formulation. This is due to the presence of both free and encapsulated DOX. The cytotoxic effect of DOX solution and DOX/ β -CDP formulation was evaluated by MTT assay against breast cancer (MCF-7) cell line. The anticancer activity of the DOX/ β -CDP was higher than the DOX.